<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864603</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH</org_study_id>
    <nct_id>NCT01864603</nct_id>
  </id_info>
  <brief_title>Sustainable East Africa Research in Community Health</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>Sustainable East Africa Research in Community Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Research Collaboration, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Bank</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States President's Emergency Plan for AIDS Relief</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SEARCH study aims to test evidenced-based innovative community based interventions that
      lead to the elimination of HIV in rural communities in East Africa using a multi-disease
      approach. The first phase of the study will quantify the impact of early HIV diagnosis using
      a streamlined and immediate ART (antiretroviral therapy). This first phase will be completed
      in July 2017. The second phase of the study, will quantify the health, economic and
      educational impact of targeted Pre-Exposure Prophylaxis (PrEP), and targeted HIV testing in
      the context of universal treatment and streamlined care. This second phase will be completed
      in July 2020. The study intervention is designed to improve the entire continuum of care, to
      reduce structural barriers for all populations including those most &quot;at risk&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SEARCH study aims to test evidenced-based innovative community based interventions that
      lead to the elimination of HIV in rural communities in East Africa using a multi-disease
      approach. The first phase of the study will quantify the health, economic and educational
      impact of early HIV diagnosis using a streamlined and immediate ART (antiretroviral therapy).
      This first phase will be completed in July 2017. The second phase of the study, will quantify
      the impact of targeted Pre-Exposure Prophylaxis (PrEP), and targeted HIV testing in the
      context of universal treatment and streamlined care. This second phase will be completed in
      July 2020. The study intervention is designed to improve the entire continuum of care, to
      reduce structural barriers for all populations including those most &quot;at risk&quot;. Primary
      endpoint for the first phase is HIV incidence measured at 3 years follow up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative HIV incidence</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV incidence</measure>
    <time_frame>3 years follow up</time_frame>
    <description>HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident TB cases associated with HIV</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare incident TB among HIV+ and HIV- populations between the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare mortality between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child mortality</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare number of child deaths between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother to child HIV transmission</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare mother to child HIV transmission between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population HIV RNA metrics</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare population HIV RNA metrics between the 2 study arms.HIV metrics include: % with HIV viral suppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between population HIV RNA metrics and HIV incidence</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To determine the association between population HIV RNA metrics and HIV incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of transmitted HIV drug-resistance mutations</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the prevalence of HIV drug-resistance mutations at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of retention in care for HIV</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare retention in care for HIV between the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ART-initiation</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare time to ART-initiation between the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate attitudes of community, patients and providers on care delivery in control and intervention communities</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To evaluate attitudes of community, patients and providers on care delivery in control and intervention communities using qualitative focus group interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate implementation of other disease care cascades (hypertension)</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Uptake of testing, linkage to care and retention to care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of chronic kidney disease (CKD)</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Number of patients with chronic kidney disease (CKD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to PrEP treatment</measure>
    <time_frame>6 years follow up</time_frame>
    <description>Number of patients who adherence to PrEP treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in attitudes towards PrEP</measure>
    <time_frame>3 years follow up</time_frame>
    <description>Qualitative focus group discussions on attitudes toward PrEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average levels of adults' on- and off-farm employment</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare the trends in average levels of adults' on- and off-farm employment between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average levels of children's on- and off-farm employment</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare the trends in average levels of children's on- and off-farm employment (child labor) between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average levels of children's time allocation to schooling and household activities</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare the trends in average levels of children's time allocation to schooling and household activities between the 2 study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs of programming</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To describe costs of programming (campaigns, ART, HTN care)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate streamlined care of HIV patients</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To evaluate streamlined vs. non-streamlined care including time and motion studies for staff and clients (Phase I only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linkage to care defined as proportion of persons attending an HIV clinic visit by 30 days after HIV test</measure>
    <time_frame>30 days after HIV test</time_frame>
    <description>To compare linkage to care with or without a phone call from clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV incidence rate</measure>
    <time_frame>3 years follow up</time_frame>
    <description>To compare HIV incidence rates between base-line and follow-up year 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355848</enrollment>
  <condition>HIV</condition>
  <condition>Tuberculosis</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Maternal Child Health</condition>
  <condition>Cost Effectiveness</condition>
  <arm_group>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery
Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1st: baseline community testing; 2nd: universal test &amp; treat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention arm first phase: baseline community-based HIV and multi-disease testing
Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal ART in a streamlined care model</intervention_name>
    <description>immediate ART start for all HIV+ in community with streamlined care</description>
    <arm_group_label>1st: baseline community testing; 2nd: universal test &amp; treat</arm_group_label>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Annual Community Health Campaigns</intervention_name>
    <description>HIV and multi-disease testing for all community members</description>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Targeted PrEP and Targeted testing interventions</intervention_name>
    <arm_group_label>1st: universal test and treat; 2nd: targeted PrEP and cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline community-based HIV and multi-disease testing</intervention_name>
    <description>HIV and multi-disease testing for all community members at baseline only</description>
    <arm_group_label>1st: baseline community testing; 2nd: universal test &amp; treat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Community Level Inclusion Criteria:

          -  Non-adjacent geopolitical units in south-western and eastern Uganda and western Kenya.

          -  Most recent census population between 9,000 and 11,000 individuals.

          -  Served by an ART providing health center.

          -  Community leader commitment for study participation and implementation.

          -  Accessibility to health center via a maintained transportation route.

          -  Community location with sufficient distance from other potential study communities to
             limit contamination of intervention or control conditions (buffer zone)

        Individual Level Inclusion Criteria:

          -  Residency of individual in community, defined as present in household for at least 6
             months of the calendar year.

        Community Level Exclusion Criteria:

          -  Presence of ongoing community-based ART intervention strategies that provide treatment
             outside of the current in-country treatment guidelines.

          -  An urban setting defined as a city with a population of 100,000 or more inhabitants.

          -  Absence of a health center able to provide ART.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Havlir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses Kamya, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maya Petersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Berkeley</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nyanza Province Kenya</name>
      <address>
        <city>Nyanza Province</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Uganda</name>
      <address>
        <city>Mbale/Tororo Region</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Uganda</name>
      <address>
        <city>Mbarara Region</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.searchendaids.com</url>
    <description>SEARCH Collaboration website</description>
  </link>
  <reference>
    <citation>Balzer LB, Petersen ML, van der Laan MJ; SEARCH Consortium. Adaptive pair-matching in randomized trials with unbiased and efficient effect estimation. Stat Med. 2015 Mar 15;34(6):999-1011. doi: 10.1002/sim.6380. Epub 2014 Nov 25.</citation>
    <PMID>25421503</PMID>
  </reference>
  <reference>
    <citation>Camlin CS, Seeley J, Viljoen L, Vernooij E, Simwinga M, Reynolds L, Reis R, Plank R, Orne-Gliemann J, McGrath N, Larmarange J, Hoddinott G, Getahun M, Charlebois ED, Bond V. Strengthening universal HIV 'test-and-treat' approaches with social science research. AIDS. 2016 Mar 27;30(6):969-70. doi: 10.1097/QAD.0000000000001008.</citation>
    <PMID>26959355</PMID>
  </reference>
  <reference>
    <citation>SEARCH Collaboration. Evaluating the feasibility and uptake of a community-led HIV testing and multi-disease health campaign in rural Uganda. J Int AIDS Soc. 2017 Mar 30;20(1):21514. doi: 10.7448/IAS.20.1.21514.</citation>
    <PMID>28406269</PMID>
  </reference>
  <reference>
    <citation>Balzer LB, van der Laan MJ, Petersen ML; SEARCH Collaboration. Adaptive pre-specification in randomized trials with and without pair-matching. Stat Med. 2016 Nov 10;35(25):4528-4545. doi: 10.1002/sim.7023. Epub 2016 Jul 19.</citation>
    <PMID>27436797</PMID>
  </reference>
  <reference>
    <citation>Balzer L, Staples P, Onnela JP, DeGruttola V. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clin Trials. 2017 Apr;14(2):201-210. doi: 10.1177/1740774516679666. Epub 2017 Jan 26.</citation>
    <PMID>28124579</PMID>
  </reference>
  <reference>
    <citation>Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, Kwariisima D, Clark TD, Petersen ML, Charlebois ED, Kamya MR, Chamie G, Havlir DV, Marquez C; SEARCH Collaboration. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):e115-e117. doi: 10.1097/QAI.0000000000001540.</citation>
    <PMID>28885271</PMID>
  </reference>
  <reference>
    <citation>Puryear SB, Balzer LB, Ayieko J, Kwarisiima D, Hahn JA, Charlebois ED, Clark TD, Cohen CR, Bukusi EA, Kamya MR, Petersen ML, Havlir DV, Chamie G. Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. AIDS. 2020 Mar 1;34(3):405-413. doi: 10.1097/QAD.0000000000002427.</citation>
    <PMID>31725431</PMID>
  </reference>
  <reference>
    <citation>Balzer LB, Havlir DV, Kamya MR, Chamie G, Charlebois ED, Clark TD, Koss CA, Kwarisiima D, Ayieko J, Sang N, Kabami J, Atukunda M, Jain V, Camlin CS, Cohen CR, Bukusi EA, van der Laan M, Petersen ML. Machine learning to identify persons at high-risk of HIV acquisition in rural Kenya and Uganda. Clin Infect Dis. 2019 Nov 7. pii: ciz1096. doi: 10.1093/cid/ciz1096. [Epub ahead of print]</citation>
    <PMID>31697383</PMID>
  </reference>
  <results_reference>
    <citation>Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED; SEARCH Collaboration. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7(8):e43400. Epub 2012 Aug 20.</citation>
    <PMID>22916256</PMID>
  </results_reference>
  <results_reference>
    <citation>Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20;27(4):627-34. doi: 10.1097/QAD.0b013e32835c54d8.</citation>
    <PMID>23169332</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb;56(4):598-605. doi: 10.1093/cid/cis881. Epub 2012 Dec 12. Erratum in: Clin Infect Dis. 2014 Aug 1;59(3):463.</citation>
    <PMID>23243180</PMID>
  </results_reference>
  <results_reference>
    <citation>Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels &gt;350 cells/μL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov;57(9):1343-50. doi: 10.1093/cid/cit490. Epub 2013 Jul 29.</citation>
    <PMID>23899683</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV; SEARCH Collaboration. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):327-32. doi: 10.1097/QAI.0000000000000021.</citation>
    <PMID>24146022</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014 Jan 2;9(1):e84317. doi: 10.1371/journal.pone.0084317. eCollection 2014.</citation>
    <PMID>24392124</PMID>
  </results_reference>
  <results_reference>
    <citation>Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV; SEARCH Collaboration. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013 Dec 9;13:1151. doi: 10.1186/1471-2458-13-1151.</citation>
    <PMID>24321133</PMID>
  </results_reference>
  <results_reference>
    <citation>Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED; SEARCH Collaboration. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr;19(4):459-68. doi: 10.1111/tmi.12273. Epub 2014 Feb 3.</citation>
    <PMID>24495307</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda. AIDS. 2014 Sep 24;28(15):2241-9. doi: 10.1097/QAD.0000000000000401.</citation>
    <PMID>25022596</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, Ayieko J, Mwangwa F, Jain V, Byonanebye D, Petersen M, Havlir D, Kamya MR. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016 May 27;11(5):e0156309. doi: 10.1371/journal.pone.0156309. eCollection 2016.</citation>
    <PMID>27232186</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016 Mar;3(3):e111-9. doi: 10.1016/S2352-3018(15)00251-9. Epub 2016 Jan 26.</citation>
    <PMID>26939734</PMID>
  </results_reference>
  <results_reference>
    <citation>Katrak S, Day N, Ssemmondo E, Kwarisiima D, Midekisa A, Greenhouse B, Kamya M, Havlir D, Dorsey G. Community-wide Prevalence of Malaria Parasitemia in HIV-Infected and Uninfected Populations in a High-Transmission Setting in Uganda. J Infect Dis. 2016 Jun 15;213(12):1971-8. doi: 10.1093/infdis/jiw057. Epub 2016 Feb 10.</citation>
    <PMID>26908725</PMID>
  </results_reference>
  <results_reference>
    <citation>Kadede K, Ruel T, Kabami J, Ssemmondo E, Sang N, Kwarisiima D, Bukusi E, Cohen CR, Liegler T, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH team. Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS. 2016 Sep 10;30(14):2121-6. doi: 10.1097/QAD.0000000000001180.</citation>
    <PMID>27258399</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts &gt;350 cells/uL in Rural Uganda. PLoS One. 2015 Dec 3;10(12):e0143433. doi: 10.1371/journal.pone.0143433. eCollection 2015.</citation>
    <PMID>26632823</PMID>
  </results_reference>
  <results_reference>
    <citation>Balzer LB, Petersen ML, van der Laan MJ; SEARCH Collaboration. Targeted estimation and inference for the sample average treatment effect in trials with and without pair-matching. Stat Med. 2016 Sep 20;35(21):3717-32. doi: 10.1002/sim.6965. Epub 2016 Apr 18.</citation>
    <PMID>27087478</PMID>
  </results_reference>
  <results_reference>
    <citation>Thirumurthy H, Jakubowski A, Camlin C, Kabami J, Ssemmondo E, Elly A, Mwai D, Clark T, Cohen C, Bukusi E, Kamya M, Petersen M, Havlir D, Charlebois ED. Expectations about future health and longevity in Kenyan and Ugandan communities receiving a universal test-and-treat intervention in the SEARCH trial. AIDS Care. 2016;28 Suppl 3:90-8. doi: 10.1080/09540121.2016.1178959.</citation>
    <PMID>27421056</PMID>
  </results_reference>
  <results_reference>
    <citation>Maeri I, El Ayadi A, Getahun M, Charlebois E, Akatukwasa C, Tumwebaze D, Itiakorit H, Owino L, Kwarisiima D, Ssemmondo E, Sang N, Kabami J, Clark TD, Petersen M, Cohen CR, Bukusi EA, Kamya M, Havlir D, Camlin CS; SEARCH Collaboration. &quot;How can I tell?&quot; Consequences of HIV status disclosure among couples in eastern African communities in the context of an ongoing HIV &quot;test-and-treat&quot; trial. AIDS Care. 2016;28 Suppl 3:59-66. doi: 10.1080/09540121.2016.1168917.</citation>
    <PMID>27421052</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Ssemmondo E, Chamie G, El Ayadi AM, Kwarisiima D, Sang N, Kabami J, Charlebois E, Petersen M, Clark TD, Bukusi EA, Cohen CR, R Kamya M, Havlir D; SEARCH Collaboration. Men &quot;missing&quot; from population-based HIV testing: insights from qualitative research. AIDS Care. 2016;28 Suppl 3:67-73. doi: 10.1080/09540121.2016.1164806.</citation>
    <PMID>27421053</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16. Erratum in: Lancet HIV. 2017 Mar;4(3):e102.</citation>
    <PMID>27989576</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Havlir DV, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED; SEARCH Collaboration. High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS. 2016 Nov 28;30(18):2855-2864.</citation>
    <PMID>27603290</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang W, Chamie G, Mwai D, Clark TD, Thirumurthy H, Charlebois ED, Petersen M, Kabami J, Ssemmondo E, Kadede K, Kwarisiima D, Sang N, Bukusi EA, Cohen CR, Kamya M, Havlir DV, Kahn JG. Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e39-e45.</citation>
    <PMID>27741031</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Black D, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV. Predictors of Retention in HIV Care Among Youth (15-24) in a Universal Test-and-Treat Setting in Rural Kenya. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18. doi: 10.1097/QAI.0000000000001390.</citation>
    <PMID>28394821</PMID>
  </results_reference>
  <results_reference>
    <citation>Ssemmondo E, Mwangwa F, Kironde JL, Kwarisiima D, Clark TD, Marquez C, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH Collaboration. Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e46-e50.</citation>
    <PMID>27741032</PMID>
  </results_reference>
  <results_reference>
    <citation>Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, Kamya M, Havlir D. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA. 2017 Jun 6;317(21):2196-2206. doi: 10.1001/jama.2017.5705.</citation>
    <PMID>28586888</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng W, Balzer L, van der Laan M, Petersen M; SEARCH Collaboration. Constrained binary classification using ensemble learning: an application to cost-efficient targeted PrEP strategies. Stat Med. 2018 Jan 30;37(2):261-279. doi: 10.1002/sim.7296. Epub 2017 Apr 6.</citation>
    <PMID>28384841</PMID>
  </results_reference>
  <results_reference>
    <citation>Mwangwa F, Chamie G, Kwarisiima D, Ayieko J, Owaraganise A, Ruel TD, Plenty A, Tram KH, Clark TD, Cohen CR, Bukusi EA, Petersen M, Kamya MR, Charlebois ED, Havlir DV, Marquez C. Gaps in the Child Tuberculosis Care Cascade in 32 Rural Communities in Uganda and Kenya. J Clin Tuberc Other Mycobact Dis. 2017 Dec;9:24-29. doi: 10.1016/j.jctube.2017.10.003.</citation>
    <PMID>29291251</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Charlebois ED, Geng E, Semitala F, Wallenta J, Getahun M, Kampiire L, Bukusi EA, Sang N, Kwarisiima D, Clark TD, Petersen ML, Kamya MR, Havlir DV. Redemption of the &quot;spoiled identity:&quot; the role of HIV-positive individuals in HIV care cascade interventions. J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25023.</citation>
    <PMID>29210185</PMID>
  </results_reference>
  <results_reference>
    <citation>Koss CA, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Balzer LB, Plenty A, Sang N, Kabami J, Ruel TD, Black D, Camlin CS, Cohen CR, Bukusi EA, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV; SEARCH Collaboration. Early Adopters of Human Immunodeficiency Virus Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda. Clin Infect Dis. 2018 Nov 28;67(12):1853-1860. doi: 10.1093/cid/ciy390.</citation>
    <PMID>29741594</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, Maeri I, Bakanoma R, Onyango A, Atwine F, Ayieko J, Kabami J, Mwangwa F, Atukunda M, Owaraganise A, Kwarisiima D, Sang N, Bukusi EA, Kamya MR, Petersen ML, Cohen CR, Charlebois ED, Havlir DV. Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study. AIDS Behav. 2020 Jul;24(7):2149-2162. doi: 10.1007/s10461-020-02780-x.</citation>
    <PMID>31955361</PMID>
  </results_reference>
  <results_reference>
    <citation>Heller DJ, Balzer LB, Kazi D, Charlebois ED, Kwarisiima D, Mwangwa F, Jain V, Kotwani P, Chamie G, Cohen CR, Clark TD, Ayieko J, Byonanabye DM, Petersen M, Kamya MR, Havlir D, Kahn JG. Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS One. 2020 Jan 15;15(1):e0222801. doi: 10.1371/journal.pone.0222801. eCollection 2020.</citation>
    <PMID>31940346</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Balzer LB, Kabami J, Kwarisiima D, Sang N, Ayieko J, Chen Y, Chamie G, Charlebois ED, Camlin CS, Cohen CR, Bukusi E, Kamya MR, Moody J, Havlir DV, Petersen ML. The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):9-15. doi: 10.1097/QAI.0000000000002199.</citation>
    <PMID>31809357</PMID>
  </results_reference>
  <results_reference>
    <citation>Olilo WA, Petersen ML, Koss CA, Wafula E, Kwarisiima D, Kadede K, Clark TD, Cohen CR, Bukusi EA, Kamya MR, Charlebois ED, Havlir DV, Ayieko J; SEARCH Collaboration. Pre-exposure Prophylaxis (PrEP) Uptake Among Older Individuals in Rural Western Kenya. J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e50-e53. doi: 10.1097/QAI.0000000000002150.</citation>
    <PMID>31490343</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamie G, Kamya MR, Petersen ML, Havlir DV. Reaching 90-90-90 in rural communities in East Africa: lessons from the Sustainable East Africa Research in Community Health Trial. Curr Opin HIV AIDS. 2019 Nov;14(6):449-454. doi: 10.1097/COH.0000000000000585.</citation>
    <PMID>31589172</PMID>
  </results_reference>
  <results_reference>
    <citation>Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, Kabami J, Sang N, Liegler T, Chamie G, Camlin CS, Jain V, Kadede K, Atukunda M, Ruel T, Shade SB, Ssemmondo E, Byonanebye DM, Mwangwa F, Owaraganise A, Olilo W, Black D, Snyman K, Burger R, Getahun M, Achando J, Awuonda B, Nakato H, Kironde J, Okiror S, Thirumurthy H, Koss C, Brown L, Marquez C, Schwab J, Lavoy G, Plenty A, Mugoma Wafula E, Omanya P, Chen YH, Rooney JF, Bacon M, van der Laan M, Cohen CR, Bukusi E, Kamya MR, Petersen M. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med. 2019 Jul 18;381(3):219-229. doi: 10.1056/NEJMoa1809866.</citation>
    <PMID>31314966</PMID>
  </results_reference>
  <results_reference>
    <citation>Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, Jain V, Clark TD, Kwarisiima D, Petersen ML, Kamya MR, Charlebois ED, Havlir DV, Marquez C; SEARCH collaboration. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care. 2020 Jan;32(1):119-127. doi: 10.1080/09540121.2019.1619661. Epub 2019 Jun 10.</citation>
    <PMID>31181961</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwarisiima D, Atukunda M, Owaraganise A, Chamie G, Clark T, Kabami J, Jain V, Byonanebye D, Mwangwa F, Balzer LB, Charlebois E, Kamya MR, Petersen M, Havlir DV, Brown LB. Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study. BMC Public Health. 2019 May 6;19(1):511. doi: 10.1186/s12889-019-6838-6.</citation>
    <PMID>31060545</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer CM, Owaraganise A, Kabami J, Kwarisiima D, Koss CA, Charlebois ED, Kamya MR, Petersen ML, Havlir DV, Jewell BL. Distance to clinic is a barrier to PrEP uptake and visit attendance in a community in rural Uganda. J Int AIDS Soc. 2019 Apr;22(4):e25276. doi: 10.1002/jia2.25276.</citation>
    <PMID>31037845</PMID>
  </results_reference>
  <results_reference>
    <citation>Camlin CS, Akullian A, Neilands TB, Getahun M, Bershteyn A, Ssali S, Geng E, Gandhi M, Cohen CR, Maeri I, Eyul P, Petersen ML, Havlir DV, Kamya MR, Bukusi EA, Charlebois ED. Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health Place. 2019 May;57:339-351. doi: 10.1016/j.healthplace.2019.05.002. Epub 2019 May 29.</citation>
    <PMID>31152972</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayieko J, Petersen ML, Charlebois ED, Brown LB, Clark TD, Kwarisiima D, Kamya MR, Cohen CR, Bukusi EA, Havlir DV, Van Rie A. A Patient-Centered Multicomponent Strategy for Accelerated Linkage to Care Following Community-Wide HIV Testing in Rural Uganda and Kenya. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):414-422. doi: 10.1097/QAI.0000000000001939.</citation>
    <PMID>30807481</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown LB, Getahun M, Ayieko J, Kwarisiima D, Owaraganise A, Atukunda M, Olilo W, Clark T, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV, Camlin CS. Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis. PLoS One. 2019 Jan 23;14(1):e0210126. doi: 10.1371/journal.pone.0210126. eCollection 2019.</citation>
    <PMID>30673744</PMID>
  </results_reference>
  <results_reference>
    <citation>Shade SB, Osmand T, Luo A, Aine R, Assurah E, Mwebaza B, Mwai D, Owaraganise A, Mwangwa F, Ayieko J, Black D, Brown LB, Clark TD, Kwarisiima D, Thirumurthy H, Cohen CR, Bukusi EA, Charlebois ED, Balzer L, Kamya MR, Petersen ML, Havlir DV, Jain V. Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Studys. AIDS. 2018 Sep 24;32(15):2179-2188. doi: 10.1097/QAD.0000000000001958.</citation>
    <PMID>30134294</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV treatment and prevention</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Community health campaign</keyword>
  <keyword>PrEP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

